06:16 AM EDT, 07/02/2026 (MT Newswires) -- Hutchmed ( HCM ) said Thursday China's National Medical Products Administration granted conditional approval to marketing application of its therapy, Orpathys, to treat certain patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

The company said the approval is based on a phase 2 study in which Orpathys achieved its primary endpoint, with an independent review committee-assessed objective response rate of 32.3%, exceeding the pre-specified efficacy threshold.

The study also reported a 63.1% disease control rate, 1.4-month median time to response, 9.7-month median duration of response, and 4-month median progression-free survival, it added.